XORTX Therapeutics (XRTX) Return on Capital Employed [ROCE] (2021 - 2026)
XORTX Therapeutics' Return on Capital Employed [ROCE] was -259.46% in the quarter ended Jun 30, 2026, down 181.38 percentage points from -78.08% a year earlier but up 260.24 percentage points from the prior quarter.
Powered by 
Analysis
XORTX Therapeutics (XRTX) Return on Capital Employed [ROCE] (2021 - 2026) Analysis & Trends
For the year ended Dec 31, 2025, Return on Capital Employed [ROCE] at XORTX Therapeutics came in at -115.27%, down 118.32 percentage points from the prior year.
- Return on Capital Employed [ROCE] shows a five-year change of +98.08 percentage points (years ended Dec 2020 to Dec 2025).
- In earlier years, Return on Capital Employed [ROCE] was 3.05% in the year ended Dec 31, 2024 (+74.60 pp), -71.56% in the year ended Dec 31, 2023 (+5.44 pp), -76.99% in the year ended Dec 31, 2022 (-141.03 pp) and 64.04% in the year ended Dec 31, 2021 (+277.39 pp).
- Quarterly Return on Capital Employed [ROCE] has moved between -519.70% (the quarter ended Mar 31, 2026) and 19.10% (the quarter ended Sep 30, 2022) over five years.
- Compared with a year earlier, Return on Capital Employed [ROCE] has declined for five straight quarters, with an average year-over-year change of -132.79 percentage points over the last eight quarters.
- The best year-over-year quarter for Return on Capital Employed [ROCE] over five years was the quarter ended Sep 30, 2024 (a gain of 53.36 percentage points); the worst was the quarter ended Mar 31, 2026 (a drop of 487.03 percentage points).
- Per Business Quant data, XRTX's Return on Capital Employed [ROCE] in the three quarters before the quarter ended Jun 30, 2026 was -519.70% (quarter ended Mar 31, 2026), -370.02% (quarter ended Dec 31, 2025) and -103.28% (quarter ended Sep 30, 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 46.74% |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 17.83% |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 17.92% |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.28% |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 19.32% |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 9.54% |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 16.66% |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | -5.97% |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 11.86% |
| 10 | XORTX Therapeutics | 1.64 Mn | -1.66 Mn | - | -259.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -259.46% |
| Mar 31, 2026 | -519.70% |
| Dec 31, 2025 | -370.02% |
| Sep 30, 2025 | -103.28% |
| Jun 30, 2025 | -78.08% |
| Mar 31, 2025 | -32.68% |
| Dec 31, 2024 | -78.86% |
| Sep 30, 2024 | -25.87% |
| Jun 30, 2024 | -32.50% |
| Mar 31, 2024 | -46.36% |
| Dec 31, 2023 | -32.06% |
| Sep 30, 2023 | -79.22% |
| Jun 30, 2023 | -62.84% |
| Mar 31, 2023 | -47.54% |
| Dec 31, 2022 | -54.58% |
| Sep 30, 2022 | 19.10% |
| Jun 30, 2022 | -25.01% |
| Mar 31, 2022 | -15.13% |
| Dec 31, 2021 | -2.63% |
API Access
XORTX Therapeutics Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=XRTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "XRTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=XRTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();